Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

References

• Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 2010;85(1):210–31.
   Web of Science ®Google Scholar
• Deval J, Selmi B, Boretto J, Egloff MP, Guerreiro C, Sarfati S, et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem. 2002;277(44):42097–104.
   Web of Science ®Google Scholar
• Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol. 2001;75(10):4832–42.
   Web of Science ®Google Scholar
• Tu X, Das K, Han Q, Bauman JD, Clark AD Jr, Hou X, et al. Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol. 2010;17(10):1202–9.
   Web of Science ®Google Scholar
• Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007;51(1):48–53.
   Web of Science ®Google Scholar
• Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, et al. K70Q adds high-level tenofovir resistance to ‘Q151M complex’ HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One. 2011;6(1):e16242.
   Web of Science ®Google Scholar
• Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis. 1996;174(5):962–8.
   Web of Science ®Google Scholar
• Van Laethem K, Pannecouque C, Vandamme AM. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infect Genet Evol. 2007;7(5):600–3.
   Web of Science ®Google Scholar
• Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology. 2004;1:2.
   Google Scholar
• Miyoshi I, Yoshimoto S, Kubonishi I, Taguchi H, Shiraishi Y, Ohtsuki Y, et al. Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Gann. 1981;72(6):997–8.
   Google Scholar
• Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of HIV-1 mutants with deletions in ‘nonessential’ genes. AIDS Res Hum Retroviruses. 1994;10(4):343–50.
   Web of Science ®Google Scholar
• Covens K, Dekeersmaeker N, Schrooten Y, Weber J, Schols D, Quinones-Mateu ME, et al. Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. J Clin Microbiol. 2009;47(7):2232–42.
   Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene. 1938;27:493–7.
   Google Scholar
• Covens K, Megens S, Dekeersmaeker N, Kabeya K, Balzarini J, De Wit S, et al. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res. 2010;86(3):253–60.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.
   Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem. 1998;19(14):1639–62.
   Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.
   Web of Science ®Google Scholar
• Maiti R, Van Domselaar GH, Zhang H, Wishart DS. SuperPose: a simple server for sophisticated structural superposition. Nucleic Acids Res. 2004;32(Web Server issue):W590–4.
   Web of Science ®Google Scholar
• Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, et al. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics. 2006;22(24):2975–9.
   Web of Science ®Google Scholar
• Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. J Gen Virol. 2010;91(Pt 8):1898–908.
   Web of Science ®Google Scholar
• Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, et al. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1. Antivir Ther. 2007;12(3):335–43.
   Web of Science ®Google Scholar
• Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother. 1996;40(9):2212–6.
   Web of Science ®Google Scholar
• Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, et al. Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2007;51(12):4489–91.
   Web of Science ®Google Scholar
• Hu Z, Hatano H, Hammond SP, Smith D, Wild M, Gupta S, et al. Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J Acquir Immune Defic Syndr. 2007;45(5):494–500.
   Web of Science ®Google Scholar
• Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134(1–2):104–23.
   Web of Science ®Google Scholar
• Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, et al. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr. 2008;48(4):428–36.
   Web of Science ®Google Scholar
• Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol. 1998;72(5):3773–8.
   Web of Science ®Google Scholar
• Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74–>Val or Ile and Val-75–>Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A. 1996;93(1):34–8.
   Web of Science ®Google Scholar
• Wirden M, Lambert-Niclot S, Marcelin AG, Schneider L, Ait-Mohand H, Brunet C, et al. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. AIDS. 2009;23(1):95–9.
   Web of Science ®Google Scholar
• Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, et al. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS. 2001;15(5):553–61.
   Web of Science ®Google Scholar
• Deforche K, Camacho RJ, Grossman Z, Soares MA, Van Laethem K, Katzenstein DA, et al. Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS. 2008;22(16):2107–15.
   Web of Science ®Google Scholar
• Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, Towner W, et al. Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother. 2009;53(11):4869–78.
   Web of Science ®Google Scholar